Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes

Laboratory Investigation

Volumn 87, Issue 8, 2007, Pages 792-806

  De Gottardi, Andrea ^a,b   Vinciguerra, Manlio ^a   Sgroi, Antonino ^a   Moukil, Moulay ^a   Ravier Dall'Antonia, Florence ^a   Pazienza, Valerio ^a   Pugnale, Paolo ^a   Foti, Michelangelo ^a   Hadengue, Antoine ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b University Hospital   (Switzerland)

Author keywords

Fatty liver disease; Immortalized human hepatocytes; Insulin signaling; Lipid metabolism; Microarrays; Steatosis

Indexed keywords

ACYL COENZYME A DESATURASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ADIPOPHILIN; ALPHA INTERFERON; ANGIOPOIETIN 1; ASPARTATE AMMONIA LIGASE; CALDESMON; CASPASE 3; CHOLESTEROL; COLLAGEN TYPE 4; COLLAGEN TYPE 8; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID; GLUTATHIONE PEROXIDASE 1; INSULIN; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; KERATIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METALLOTHIONEIN II; MYOSIN; OLEIC ACID; PERIPLAKIN; PEROXIREDOXIN; SELENOPROTEIN W; STEFIN A; SYNDECAN 4; THROMBOMODULIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY LIVER; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; LIVER INJURY; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THIN LAYER CHROMATOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FATTY LIVER; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; OLEIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 34447555806     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700590     Document Type: Article

References (55)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
2. Harrison SA, Diehl AM. Fat and the liver - a molecular overview. Semin Gastrointest Dis 2002;13:3-16.
3. Mager DR, Roberts EA. Nonalcoholic fatty liver disease in children. Clin Liver Dis 2006;10:109-131, vi-vii.
4. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-1466.
5. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003;52:288-292.
6. Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-842.
7. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
8. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
9. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-1493.
10. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006;290:G194-G198.
11. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002;35:898-904.
12. Letteron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003;38:133-140.
13. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
14. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-G1139.
15. Galli A, Svegliati-Baroni G, Ceni E, et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005;41:1074-1084.
16. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
17. Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005;17:837-841.
18. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006;44:190-196.
19. Matsumoto M, Han S, Kitamura T, et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006;116:2464-2472.
20. Azzout-Marniche D, Becard D, Guichard C, et al. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000;350(Part 2):389-393.
21. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
22. Matsumoto M, Ogawa W, Teshigawara K, et al. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 2002;51:1672-1680.
23. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005;115:718-727.
24. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443.
25. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004;39:1230-1238.
26. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301-1311.
27. Chiappini F, Barrier A, Saffroy R, et al. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab Invest 2006;86:154-165.
28. Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-251.
29. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-674.
30. Nguyen TH, Mai G, Villiger P, et al. Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J Hepatol 2005;43:1031-1037.
31. Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003;31:e73.
32. Folch J, Ascoli I, Lees M, et al. Preparation of lipide extracts from brain tissue. J Biol Chem 1951;191:833-841.
33. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917.
34. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
35. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
36. Farinati F, Cardin R, Bortolami M, et al. The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. J Hepatol 2003;39:292-294.
37. Selzner M, Clavien PA. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 2000;31:35-42.
38. Yang SQ, Lin HZ, Mandal AK, et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001;34:694-706.
39. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078-1087.
40. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002;1585:202-212.
41. Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology 2003;124:1451-1464.
42. Uetsuka K, Shirai M, Yamauchi H, et al. Impaired proliferation of nonparenchymal cells participates in an impairment of liver regeneration in db/db mice. Exp Mol Pathol 2005;79:51-58.
43. Masuda Y, Itabe H, Odaki M, et al. Adipose differentiation-related protein is degraded through the proteasome-dependent pathway during regression of lipid-storing cells. J Lipid Res 2005;47:87-98.
44. Okamoto Y, Tanaka S, Haga Y. Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol Res 2002;23:138-144.
45. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-194.
46. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-1133.
47. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
48. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
49. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-32353.
50. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
51. Shimomura I, Matsuda M, Hammer RE, et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86.
52. Sun Y, Liu S, Ferguson S, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem 2002;277:23301-23307.
53. Thirone AC, Huang C, Klip A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 2006;17:72-78.
54. Dong X, Park S, Lin X, et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 2006;116:101-114.
55. Swagell CD, Henly DC, Morris CP. Expression analysis of a human hepatic cell line in response to palmitate. Biochem Biophys Res Commun 2005;328:432-441.